Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Briggs

Showing results (111-120 of 229) with videos related to

Pageof 23
Sort By:
Journal of Comparative Effectiveness Research|June 1, 2018
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonistsMike Dolph, Anuja Roy, Menaka Bhor, et al.
Pharmacoeconomics|July 2, 2022
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the USHardik Goswami, Adnan Alsumali, Yiling Jiang, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 29, 2014
Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect InformationJonathan D Campbell, R Brett McQueen, Anne M Libby, et al.
BMJ (Clinical Research Ed.)|February 5, 2008
Value based pricing for NHS drugs: an opportunity not to be missed?Karl Claxton, Andrew Briggs, Martin J Buxton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2022
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With CancerXiaoliang Wang, Blythe J Adamson, Andrew Briggs, et al.
Pharmacoeconomics|March 17, 2023
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the USHardik Goswami, Adnan Alsumali, Yiling Jiang, et al.
International Journal of Rheumatology|January 29, 2010
Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association databaseJohn Oldroyd, Lionel Schachna, Rachelle Buchbinder, et al.
Health Economics|June 19, 2023
Estimating health care costs at scale in low- and middle-income countries: Mathematical notations and frameworks for the application of cost functionsMarc d'Elbée, Fern Terris-Prestholt, Andrew Briggs, et al.
BMJ Open|August 20, 2017
Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trialZahidul Quayyum, Andrew Briggs, Jose Robles-Zurita, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaMargaret Hux, Denise Zou, Esprit Ma, et al.
Pageof 23

Showing results (111-120 of 229) with videos related to

Sort By:
Pageof 23
Journal of Comparative Effectiveness Research|June 1, 2018
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonistsMike Dolph, Anuja Roy, Menaka Bhor, et al.
Pharmacoeconomics|July 2, 2022
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the USHardik Goswami, Adnan Alsumali, Yiling Jiang, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 29, 2014
Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect InformationJonathan D Campbell, R Brett McQueen, Anne M Libby, et al.
BMJ (Clinical Research Ed.)|February 5, 2008
Value based pricing for NHS drugs: an opportunity not to be missed?Karl Claxton, Andrew Briggs, Martin J Buxton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 31, 2022
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With CancerXiaoliang Wang, Blythe J Adamson, Andrew Briggs, et al.
Pharmacoeconomics|March 17, 2023
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the USHardik Goswami, Adnan Alsumali, Yiling Jiang, et al.
International Journal of Rheumatology|January 29, 2010
Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association databaseJohn Oldroyd, Lionel Schachna, Rachelle Buchbinder, et al.
Health Economics|June 19, 2023
Estimating health care costs at scale in low- and middle-income countries: Mathematical notations and frameworks for the application of cost functionsMarc d'Elbée, Fern Terris-Prestholt, Andrew Briggs, et al.
BMJ Open|August 20, 2017
Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trialZahidul Quayyum, Andrew Briggs, Jose Robles-Zurita, et al.
Journal of Health Economics and Outcomes Research|September 4, 2023
A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaMargaret Hux, Denise Zou, Esprit Ma, et al.
Pageof 23